These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 31648843)
21. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265 [TBL] [Abstract][Full Text] [Related]
22. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Meltzer HY; Huang M Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033 [TBL] [Abstract][Full Text] [Related]
23. Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. Shim JC; Kim YH; Kelly DL; Lee JG; Conley RR J Neuropsychiatry Clin Neurosci; 2005; 17(2):221-6. PubMed ID: 15939977 [TBL] [Abstract][Full Text] [Related]
24. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Sumiyoshi T; Matsui M; Nohara S; Yamashita I; Kurachi M; Sumiyoshi C; Jayathilake K; Meltzer HY Am J Psychiatry; 2001 Oct; 158(10):1722-5. PubMed ID: 11579010 [TBL] [Abstract][Full Text] [Related]
25. Serotonin receptors: their key role in drugs to treat schizophrenia. Meltzer HY; Li Z; Kaneda Y; Ichikawa J Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974 [TBL] [Abstract][Full Text] [Related]
26. Current Treatment Options and Emerging Agents for Schizophrenia. Correll CU J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32297721 [TBL] [Abstract][Full Text] [Related]
27. Lifetime use of psychiatric medications and cognition at 43years of age in schizophrenia in the Northern Finland Birth Cohort 1966. Hulkko AP; Murray GK; Moilanen J; Haapea M; Rannikko I; Jones PB; Barnett JH; Huhtaniska S; Isohanni MK; Koponen H; Jääskeläinen E; Miettunen J Eur Psychiatry; 2017 Sep; 45():50-58. PubMed ID: 28728095 [TBL] [Abstract][Full Text] [Related]
28. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123 [TBL] [Abstract][Full Text] [Related]
29. Atypical antipsychotics and inverse agonism at 5-HT2 receptors. Sullivan LC; Clarke WP; Berg KA Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975 [TBL] [Abstract][Full Text] [Related]
30. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. Ozzoude M; Nakajima S; Plitman E; Chung JK; Kim J; Iwata Y; Caravaggio F; Takeuchi H; Uchida H; Graff-Guerrero A; Gerretsen P Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():207-213. PubMed ID: 30172739 [TBL] [Abstract][Full Text] [Related]
31. An investigation into the relationship between clozapine treatment and cognitive performance in patients with treatment resistant schizophrenia. McArdle PA; De Mel V; DeMonte V; Winckel K; Gore-Jones V; Foley S; Korman N; Parker S; Dark F; Siskind D Schizophr Res; 2019 Apr; 206():450-451. PubMed ID: 30527271 [No Abstract] [Full Text] [Related]
32. Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: An antipsychotic dose reduction study. Gerretsen P; Takeuchi H; Ozzoude M; Graff-Guerrero A; Uchida H Psychiatry Res; 2017 May; 251():20-25. PubMed ID: 28187335 [TBL] [Abstract][Full Text] [Related]
33. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282 [TBL] [Abstract][Full Text] [Related]
34. Brexpiprazole for the treatment of schizophrenia. Hsu WY; Lane HY; Lin CH Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809 [TBL] [Abstract][Full Text] [Related]
35. Pharmacologic management of aggression in the elderly. Yudofsky SC; Silver JM; Hales RE J Clin Psychiatry; 1990 Oct; 51 Suppl():22-8; discussion 29-32. PubMed ID: 1976621 [TBL] [Abstract][Full Text] [Related]